Financial Data and Key Metrics Changes - Revenue grew 41% year over year to $18.6 million, up from $13.2 million in Q1 of last year [5] - Net income surged to $2.59 million, a 737% increase over Q1 2024 [5] - Adjusted EBITDA jumped 193% to $4.9 million, with gross margin expanding over 10 points to 62.9% [5][6] Business Line Data and Key Metrics Changes - Patient Affordability business revenues rose 261% year over year to $8.6 million, with claims processed growing by more than 160% [6] - Plasma donor compensation revenue decreased 9.2% to $9.4 million, with revenue per plasma center declining to $6,517 [10][14] Market Data and Key Metrics Changes - The Patient Affordability segment accounted for 46.3% of quarterly revenues, a significant increase from 18.1% in the same period last year [15] - The company ended the quarter with 484 plasma centers, adding four new centers during the period [10][14] Company Strategy and Development Direction - The acquisition of Gamma Innovation is expected to enhance the tech stack and offer a full front-end engagement platform integrated with core payment solutions [11][12] - The company aims to unlock additional revenue streams and expand its total addressable market beyond the plasma sector into broader pharmaceutical and healthcare sectors [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory and commitment to delivering long-term value to shareholders [13] - The company expects patient affordability revenue to more than double again in 2025 based on current pipeline and results [8] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt [17] - Full-year gross profit margins are expected to be between 62% to 64%, reflecting stable margins in the plasma business and increased contributions from the higher-margin pharma patient affordability business [18] Q&A Session Summary - No questions were raised during the Q&A session [21]

Paysign (PAYS) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good afternoon. My name is Chelsea, and I will be your conference operator today. At this time, I would like to welcome everyone to the PaySign, Inc. First Quarter twenty twenty five Earnings Conference Call. After the speakers' remarks, there will be a question and answer session. As a reminder, this conference is being recorded. The comments on today's call regarding PaySign's financial results will be on a GAAP basis unless otherwise ...

Core Insights - The article emphasizes the importance of identifying stocks that can exceed market expectations during earnings season, highlighting a selection of companies likely to outperform [1][4]. Stock Selection Criteria - A screening process identified five stocks: Fox (FOXA), Newmont (NEM), Affirm (AFRM), HealthStream (HSTM), and Iridium Communications (IRDM) as potential earnings beaters [1][10]. - The selection criteria included: - Last EPS Surprise greater than or equal to 10% [7] - Average EPS Surprise in the last four quarters greater than 20% [7] - Average EPS Surprise in the last two quarters greater than 20% [8] - Zacks Rank less than or equal to 2 [8] - Earnings ESP greater than zero [9] - Next 3–5 Years Estimated EPS Growth (Per Year) greater than 10% [10] - Average 20-day Volume greater than 100,000 [10] Company Profiles - **Fox (FOXA)**: A Zacks Rank 1 company with an average earnings surprise of 24.20% over the past four quarters [11]. - **Newmont (NEM)**: A Zacks Rank 2 company, one of the largest gold producers globally, with an average earnings surprise of 32.41% [11]. - **Affirm (AFRM)**: A Zacks Rank 1 financial technology company specializing in payment solutions, boasting an average earnings surprise of 84.09% [12]. - **HealthStream (HSTM)**: A Zacks Rank 1 company providing workforce development solutions in healthcare, with an average earnings surprise of 42.02% [13]. - **Iridium Communications (IRDM)**: A Zacks Rank 2 satellite communications company, achieving an average earnings surprise of 40.90% [14].